Edition:
United Kingdom

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

10.97USD
14 Aug 2018
Change (% chg)

$0.26 (+2.43%)
Prev Close
$10.71
Open
$10.70
Day's High
$11.05
Day's Low
$10.70
Volume
55,727
Avg. Vol
73,761
52-wk High
$17.90
52-wk Low
$4.93

Chart for

About

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement... (more)

Overall

Beta: --
Market Cap(Mil.): $326.48
Shares Outstanding(Mil.): 22.61
Dividend: --
Yield (%): --

Financials

  RARX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.20 -- --
ROI: -60.75 1.78 14.61
ROE: -174.09 3.28 16.33

BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock

* RA PHARMA - ENTERED SALES AGREEMENT WITH STIFEL PURSUANT TO WHICH CO MAY SELL, UP TO $50 MILLION OF SHARES OF COMMON STOCK, THROUGH STIFEL AS SALES AGENT Source text: (https://bit.ly/2G0vejI) Further company coverage:

09 May 2018

BRIEF-Ra Pharmaceuticals Q1 Loss Per Share $0.61

* RA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Ra Pharmaceuticals Announces Presentation Of RA101495 SC Phase 2 gMG Clinical Trial Design At 70Th Annual AAN Meeting

* RA PHARMACEUTICALS ANNOUNCES PRESENTATION OF RA101495 SC PHASE 2 GMG CLINICAL TRIAL DESIGN AT THE 70TH ANNUAL AAN MEETING

25 Apr 2018

BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67

* RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

14 Mar 2018

Earnings vs. Estimates